Newain , an electronic drug research and development company, announced on the 12th that it participated in the '2025 Korean Academy of Child and Adolescent Psychiatry Spring Conference' held on May 9th and introduced the results of a clinical trial of trigeminal nerve electrical stimulation targeting patients with autism spectrum disorder (ASD) and its mental healthcare product 'WITHNOX'.
This academic conference was held with a large number of domestic pediatric and adolescent mental health experts in attendance, and was designed to share the latest research trends and treatment techniques. Newain operated an exhibition booth, interacted with medical experts, and introduced the possibilities and development directions of electronic drug-based ADHD treatment technology.
At the event, the results of the ASD exploratory clinical trial based on trigeminal nerve electrical stimulation, jointly conducted by Newain and Professor Yoo Hee-jung of Seoul National University Bundang Hospital, were also announced. The clinical trial was a non-invasive treatment approach using electrical stimulation, and was reported to have shown significant improvement effects in major evaluation items such as sociality, emotional regulation, and sleep. In addition, it was evaluated that the positive results in terms of safety were confirmed, increasing the possibility of applying electronic drug technology.
In addition, Newain also introduced the wellness device 'WITHNOX' that utilizes electronic medicine technology. The product is a non-drug-based solution that stimulates the trigeminal nerve in the forehead area during sleep to induce prefrontal nerve activity and help improve concentration and sleep quality. It has currently completed domestic KC certification and is being sold to general consumers through its Naver store. A two-month trial sales method is also being implemented.
A representative of Newain said, “This academic conference was a meaningful opportunity to communicate directly with medical experts and share various perspectives on pediatric and adolescent mental health,” and added, “We plan to continue developing personal medical devices and healthcare products based on clinical data and research results in the future.”
- See more related articles
You must be logged in to post a comment.